Viewing Study NCT00845650


Ignite Creation Date: 2025-12-24 @ 5:18 PM
Ignite Modification Date: 2025-12-31 @ 6:26 AM
Study NCT ID: NCT00845650
Status: COMPLETED
Last Update Posted: 2024-03-18
First Post: 2009-02-13
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
Sponsor: Emergent BioSolutions
Organization:

Study Overview

Official Title: A Randomized, Double-Blind, Dose-Escalation Study Evaluating Pharmacokinetics and Safety of Anthrax Immune Globulin Intravenous (AIGIV)
Status: COMPLETED
Status Verified Date: 2024-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to:

* evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) as compared with either 90 mg/kg, 180 mg/kg or 360 mg/kg total IgG, GAMUNEX® (immune globulin intravenous (human) 10% caprylate/chromatography purified). GAMUNEX is a trademark of Talecris Biotherapeutics.
* evaluate the pharmacokinetic (PK) profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) as measured by lethal toxin neutralizing antibody (TNA).
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
DMID 07-0067 OTHER NIAID View
HHSN272200700034C OTHER_GRANT NIAID View